Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 178

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 178
---
 US, Vaxelis became market leader at the end of 2023 in the three-dose primary series market. As a reminder, sales of Vaxelis in the United States are not consolidated, and the profits are shared equally between Sanofi and Merck & Co. The Beyfortus launch began in late September 2023, in the United States and Europe. Sales of the product reached € 547 million in 2023 , reflecting strong demand through All Infant Protection Programs rolled out in United States, Spain and France . Net sales of Meningitis, Travel and Endemics Vaccines for 2023 reached € 1,266 million, up 0.5% CER, with 40.2% growth in Europe more than offsetting lower sales in the Rest of the World region ( -7.4% CER) and the United States ( -0.8% CER at € 730 million), reflecting a favorable pattern in the US, while the divestment of the Japanese Encephalitis vaccine in 2022 impacted the Rest of the World region. 4/ Net sales by geographical region The table below sets forth our net sales for 2023 and 2022 by geographical region:

| (€ million)       |   2023 |   2022 | Change ona reported basis | Change at constantexchange rates |
| United States     | 17,262 | 16,986 | +1.6%                     | +5.2%                            |
| Europe            |  8,816 |  8,490 | +3.8%                     | +4.2%                            |
| Rest of the World | 11,739 | 12,175 | -3.6%                     | +6.4%                            |
| of which China    |  2,728 |  2,950 | -7.5%                     | -0.3%                            |
| Total net sales   | 37,817 | 37,651 | +0.4%                     | +5.4%                            |

In 2023 , net sales in the United States reached € 17,262 million, up 5.2% at CER, reflecting a strong performance from Dupixent (+ 32.6% CER at € 8,145 million) and the launches of Beyfortus (€ 407 million) and ALTUVIIIO, (€ 155 million)